Laennec

Laennec is a human placenta hydrolysate - a broth of peptides, free amino acids, and trace growth factors (notably HGF, EGF, FGF) extracted from donated human placentas - manufactured by Green Cross Wellbeing in South Korea, where it has been sold for decades for chronic liver disease and menopausal symptoms [1]. The ongoing Phase 3 NCT06493799 is not a placebo-controlled efficacy study but a 226-patient head-to-head comparison of intravenous (10 mL) versus subcutaneous (4 mL) dosing, twice weekly for six weeks, in patients with alcoholic and non-alcoholic fatty liver disease [2]. For a Western pharma audience, this is a regulatory and scientific outlier: a product with regional approval, undefined molecular target, and no realistic path to FDA registration in its current form.

Laennec is approved in South Korea (Green Cross Wellbeing) and Japan (a sister product, Melsmon, plus the original Laennec marketed by Japan Bio Products) for chronic hepatic dysfunction, fatigue, and menopausal indications [1]. It has never been approved by the FDA or EMA, and there is no active U.S. IND or BLA program disclosed (IND = Investigational New Drug application, the gate to U.S. human studies; BLA = Biologics License Application, the registration filing for biologics). The current Phase 3 is a single-country South Korean study, NCT06493799, sponsored by Green Cross Wellbeing - a lifecycle study, not a registration trial for a new market [2]. There are no FDA designations: no breakthrough, no fast track, no orphan, no priority review. Expected readout has not been disclosed publicly; the trial is in recruitment. Treat this as a regional product optimizing its label, not a novel therapeutic on a Western approval clock. Public revenue figures for Laennec specifically are not broken out, but placental hydrolysates are believed to generate at least mid-eight-figures USD annually across Korea and Japan - meaningful enough to justify lifecycle defense, far short of a global asset. If you are tracking this for U.S. commercial relevance, the answer today is zero. If you are tracking it as a marker of how Korean biologics may eventually pursue ICH (International Council for Harmonisation)-grade evidence packages of the kind Western regulators accept, it is a small data point - nothing more.

Laennec is an extract, not a defined molecule. Placentas are collected from screened donors, then enzymatically digested and filtered to produce a soup of low-molecular-weight peptides, free amino acids, nucleotides, and trace cytokines and growth factors - published characterizations identify hepatocyte growth factor (HGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF) among the bioactive components [3]. The proposed mechanism for liver disease is that this mixture supplies the regenerating liver with amino acid building blocks and signaling peptides that nudge hepatocyte (the main liver cell type, responsible for metabolism and regeneration) proliferation and dampen inflammation, with rodent work pointing to the HGF/c-Met pathway as a candidate route [3]. Preclinical evidence in carbon-tetrachloride and alcohol-induced liver injury models in rats shows reduced fibrosis and improved liver enzymes [3]. But there is no defined active ingredient, no characterized single receptor, no human pharmacokinetic profile of any specific component. Compare this to a small molecule like obeticholic acid, where you can name the receptor (FXR - a nuclear receptor that senses bile acids and tunes liver metabolism) and explain why activating it should reduce fibrosis. Laennec has no equivalent story. By the standards of mechanism-based drug development, this is closer to a traditional medicine product with a modern manufacturing process than to a 21st-century biologic. Honesty matters here: the mechanism case is weak by Western standards, and regulators will treat it as such if it ever lands on their desk.

NCT06493799 is a Phase 3 open-label randomized study comparing intravenous Laennec (10 mL) against subcutaneous Laennec (4 mL), dosed twice weekly for six weeks, in 226 patients (1:1 allocation) with chronic liver disease - both alcoholic liver disease and non-alcoholic fatty liver disease (now called MASLD in current nomenclature) [2]. There is no placebo arm. There is no active comparator drug. The design strongly suggests a non-inferiority framework (designed to show the new route is no worse than the old, not that it is better) for liver function markers - ALT and AST (alanine and aspartate aminotransferase, liver enzymes that leak into blood when hepatocytes are damaged) and possibly fibrosis scores - with the commercial goal of expanding the label to include subcutaneous dosing for outpatient convenience. This is a route-of-administration trial dressed in Phase 3 clothing. It will not generate the kind of data a Western payer or regulator would treat as evidence of efficacy against MASLD - for that, you need biopsy-confirmed fibrosis improvement against placebo, which is what Madrigal demonstrated with resmetirom in MAESTRO-NASH. The competitive context is brutal: obeticholic acid (OCA, Intercept) was rejected by FDA for NASH twice, most recently in June 2023 after a 12-2 advisory committee vote against approval citing drug-induced liver injury and other safety concerns [7]; elafibranor failed its NASH Phase 3 RESOLVE-IT trial in 2020 but was later approved by the FDA for primary biliary cholangitis (PBC) - a different liver disease - as Iqirvo in June 2024 [5,8]; and semaglutide is now generating real Phase 3 MASH data in the ESSENCE trial. Read NCT06493799 as a Korean lifecycle management exercise, not a key efficacy readout.

Our model gives this drug a 16% chance of eventually being approved. That number starts from the historical approval rate for Phase 3 drugs in this area - about 54% - then adjusts based on ten specific facts about the trial and its sponsor. The biggest downward pulls are the sponsor's weak approval record, limited earlier-phase results, a randomized trial design, and the use of a comparator arm. Most other factors are close to average for this stage and don't shift the estimate much either way.

Efficacy risk is moderate for the narrow non-inferiority question, severe for any extrapolation to MASLD efficacy. The trial is comparing two routes of the same product - if both work or both don't, you cannot tell from this design whether Laennec is doing anything to liver disease. Safety risk includes the obvious biologic issue: human-derived material carries theoretical pathogen transmission risk (viral, prion), and while Korean and Japanese manufacturers have decades of safety data and screening protocols [1], this is the exact category of risk that has kept human-derived placental products out of FDA-friendly markets. Regulatory risk outside Korea is essentially total - no Western agency will register a poorly characterized placental extract on this dataset, full stop. Commercial risk is the most interesting one. Even within Korea, the placental extract market faces growing scrutiny from payers who want mechanism-based evidence. Green Cross Wellbeing is running this trial partly to defend a legacy revenue stream, not to expand into a growing one. The deeper risk is irrelevance: while Laennec runs a route-comparison study, Madrigal's resmetirom (Rezdiffra) generated $180M in 2024 and $958M in 2025 [6,9] - a clear billion-dollar trajectory - with a clean mechanism, biopsy data, and a competitive set (semaglutide ESSENCE, lanifibranor NATiV3) that does not include Laennec.

Noise for U.S. biotech investors. Signal - barely - for anyone tracking Korean pharma's evolving evidence standards. The trial will most likely read out as non-inferior, Laennec will get a subcutaneous label expansion in Korea, and nothing about the global hepatology field will change. The data point worth watching is not the trial result but whether Green Cross Wellbeing or any other Asian sponsor ever commits to a placebo-controlled biopsy-endpoint MASH study with this product - that would be the first real signal that placental hydrolysates are being taken seriously as drugs rather than as legacy traditional medicines. Until then, this node sits in the BioCosm map as a useful reminder that 'Phase 3' is not a uniform unit of evidence: a Phase 3 route-comparison in 226 Korean patients and a Phase 3 head-to-head against pembrolizumab carry the same label and radically different commercial meaning. Check back when the trial completes (no public date yet) or when Green Cross Wellbeing discloses next-stage development plans in their annual reports.